item management s discussion and analysis of financial condition and results of operation the following discussion should be read in conjunction with the information contained in the consolidated financial statements  including the related notes  and the other financial information incorporated by reference herein 
risk factors 
in connection with the safe harbor provisions of the private securities litigation reform act of  the company hereby makes reference to items set forth under the heading risk factors in the company s registration statement on form s  as amended registration no 

such cautionary statements identify important facts that could cause the company s actual results to differ materially from those projected in forward looking statements made by or on behalf of the company in this or any other section of this annual report on form k 
general capstone is a leading provider of institutional pharmacy services to long term care facilities and correctional institutions throughout the united states 
the company provides its long term care clients with comprehensive institutional pharmacy services that include i the purchasing  repackaging and dispensing of pharmaceuticals  ii infusion therapy and medicare part b services  which are comprised of enteral nutrition and urologic supplies  and iii pharmacy consulting services  all of which are supported by computerized recordkeeping and third party billing services 
the company serves its long term care clients primarily through regional pharmacies that are open hours  seven days a week 
in the correctional business  the company provides pharmaceuticals primarily under capitated contracts at correctional institutions that have privatized inmate health care services 
health care providers are continuing to be challenged to reduce costs while maintaining the quality of patient care 
management believes that these factors will result in the continuing consolidations of institutional pharmacy providers during the new few years 
in addition  the company believes that its strategy of creating larger regional pharmacies in metropolitan areas will allow it to reduce the costs of providing services to the residents it serves 
the company is also developing a formulary and various other clinical programs which it believes will enhance the quality of patient care while reducing the costs of providing this care 
in may  the company implemented a corporate restructuring plan that included installation of a new management team  refocusing the company s operations on core institutional pharmacy businesses and the initiation of an aggressive acquisition strategy 
in conjunction with the restructuring  the company exited certain non strategic  unprofitable lines of business 
the company sold its medical surgical supply operation  closed a long term care pharmacy in missouri  discontinued its long term care mail order pharmacy operations and sold its computer software division 
the company took certain charges and realized certain gains relating to the discontinuation of these operations 
during the third quarter of  the company implemented a restructuring plan that will consolidate and integrate the company s recent acquisitions with existing operations  as well as promote an efficient structure to support continued growth 
key aspects of this plan include the consolidation of california  pennsylvania and maryland long term care pharmacies and the closure of excess facilities 
the company will relocate its corporate headquarters to irving  texas during the acquisition of institutional pharmacy companies has resulted in a significant change in the company s financial profile 
since may  the company has completed acquisitions 
on a pro forma basis for all acquisitions  the company s net sales and net income for the year ended december   were  and  respectively  compared to actual net sales of  and  of net income 
all of these acquisitions have been accounted for using the purchase method of accounting  and as a result the company will incur significant future amortization expense associated with goodwill 
fiscal year ended december  compared to the ten months ended december net sales 
net sales increased to  in from  in  an increase of  or 
this increase is primarily attributable to the acquisition of symphony and other institutional pharmacy businesses during additionally  the company anticipates that continued acquisitions of institutional pharmacies will be a significant contributor to revenue growth in the next few years 
net revenue in will also be higher than as a result of realizing a full year s contribution from businesses that were acquired during in addition to growth through acquisitions  the company anticipates net revenues will increase in future years as a result of new contracts  preferred provider agreements and the increase in ancillary services provided such as infusion therapy and medicare part b services 
cost of sales 
cost of sales includes the cost of pharmaceuticals sold to patients and institutions 
cost of sales increased to  in from  in an increase of  or 
the increase in dollar amount of cost of sales is due to the corresponding increase in revenue levels for as a percentage of net sales  cost of sales decreased to in from in this is a result of more favorable reimbursement in the markets of the acquired companies  the addition of higher margin infusion therapy  medicare part b services and purchasing efficiencies related to greater purchasing volume 
in addition  the company entered into a new prime vendor and group purchasing organization agreements during the fourth quarter of the company anticipates that these agreements will result in a further reduction in the cost of pharmaceuticals purchased in selling  general and administrative expenses 
selling  general and administrative expenses include salaries  benefits  facility and delivery expenses and other administrative overhead 
selling  general and administrative expenses increased to  in from  in  an increase of  or 
the increase in the amount of selling  general and administrative expenses during was due to the six acquisitions finalized in as a percentage of net sales  selling  general and administrative expenses were in the period compared to in the period 
this decrease is a result of the corporate restructuring discussed above and initial operational synergies achieved through the acquisition of symphony 
depreciation and amortization 
depreciation and amortization increased to  in from  in  an increase of  or 
this increase is attributable to assets and goodwill associated with acquisitions completed during non operating expense 
non operating expenses include interest  acquisition financing fees and expenses and other non operating items 
non operating expenses increased to  in from  in during  the increase in non operating expenses is attributable to one time charges of  related to acquisition financing fees for the symphony transaction and increased interest expense primarily resulting from borrowings related to acquisitions 
the ten months ended december  include a gain on the sale of the company s medical surgical business 
income taxes 
income taxes in the and periods consist of accruals for estimated state and local incomes taxes based upon apportioned state taxable income  offset by estimated refundable federal income taxes resulting from the benefit of net operating loss carryforwards 
in  the company realized a benefit for income taxes of  which was primarily a result of the reversal of a deferred tax asset valuation allowance established in prior periods 
ten months ended december  compared with the fiscal year ended february net sales 
net sales for the ten months ended december  were  compared to  for the fiscal year ended february  of this difference  net revenues increased by approximately  due to the acquisition of premier 
net sales decreased substantially due to the sale of the medical surgical business  partially offset by the addition of new correctional contracts 
cost of sales 
cost of sales for the ten months ended december  was  compared to  for the fiscal year ended february  of this difference  approximately  was attributable to the premier acquisition 
as a percentage of net sales  cost of sales for the ten months ended december  was compared to for fiscal the decrease as a percentage of net sales was primarily due to the sale of the lower margin medical surgical supply business 
in addition  the company renegotiated its purchasing contracts during the period  lowering its cost of sales 
selling  general and administrative expenses 
selling  general and administrative expenses for the ten months ended december  were  compared to  for the fiscal year ended february  as a percentage of net sales  selling  general and administrative expenses for the ten months ended december  were compared to for fiscal the decrease as a percentage of net sales was due to the sale of the medical surgical supply business and reduced costs as a result of the corporate restructuring discussed above 
the premier acquisition added approximately  of additional selling  general and administrative expense 
interest expense 
net interest expense for the ten months ended december  was  compared to  for the fiscal year ended february  this decrease primarily resulted from the reduction of the company s debt using proceeds from private placements and the difference between the ten month and twelve month periods 
other income 
other income for the ten months ended december  was  compared to  for the fiscal year ended february  the difference primarily resulted from a gain on the sale of assets from the company s medical surgical supply business 
income taxes 
benefit for income taxes for the ten months ended december  was  compared to  for the fiscal year ended february  the benefit for income taxes for the ten months ended december   primarily resulted from the carry back of a prior year taxable loss to prior periods 
liquidity  capital resources and cash flow the company requires capital primarily for the acquisition of institutional pharmacy companies  to finance its working capital requirements and for the purchase of equipment for existing pharmacies 
the company s net cash flows from operating activities were   and  respectively  for the year ended december   the ten months ended december   and the year ended february   respectively 
generally  the cash flows from operating activities in each of the periods resulted from increased working capital requirements associated with the company s acquisitions 
during  cash flows from operations were affected primarily by cash paid for acquisition financing fees related to the symphony acquisition of  net cash from operating activities was impacted by a  net loss and a  litigation settlement payment by the company in the fiscal year ended february  these capital needs are met through bank financing  and private and public equity offerings 
the continuing availability of capital is crucial to the company s future acquisition strategy 
there can be no assurance that additional financing will be available to the company on terms acceptable to the company or at all 
the company s net cash flows for investing activities were   and  for the year ended december   the ten months ended december  and the year ended february   respectively 
the company s net cash to investing activities were primarily impacted by  related to the acquisition of geri care  imd  medidyne  symphony  happy harry s and institutional pharmacy services during and by  of acquisition spending for premier  and a  advance associated with a subsequent acquisition during the ten months ended december  net cash flows from financing activities were approximately   and  for the year ended december   the ten months ended december  and the year ended february   respectively 
net cash flows from financing activities were impacted by public and private equity offerings for net proceeds of  net borrowings of  and  related to symphony acquisition financing fees in net cash flows from financing activities in were impacted by equity offerings for net proceeds of  and net debt repayments of  in the ten months ended december  during december  the company entered into a revolving million credit facility the credit facility with a syndicate of banks for which bankers trust company acts as agent 
approximately  of the credit facility was used to retire amounts outstanding under the company s prior credit facility 
borrowings under the agreement are secured by substantially all of the assets of the company 
the credit facility bears interest  at the option of the company  at a bankers trust company s prime rate plus between to  based on the company s leverage ratio  or b the prevailing eurodollar rate quoted by bankers trust company  plus between 
to  based on the company s leverage ratio 
borrowings under the credit facility are subject to other provisions and covenants  all as defined by the underlying agreement 
the company incurred an extraordinary loss of approximately  related to the retirement 
as of march   the company had outstanding borrowings of approximately  under the credit facility 
the company s current ratio was at december  and at december  the increased current ratio at december  was due primarily to an increase in accounts receivable  inventories and prepaid expenses partially offset by increases in accounts payable  accrued expenses and other current liabilities  all as a result of acquisitions 

